With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6258-28-2,2-(2,6-Dioxopiperidin-4-yl)acetic acid,as a common compound, the synthetic route is as follows.
6258-28-2, Example 117 (2R)-N-(4-tert-butyl-3-fluorophenyl)-2-(((2,6-dioxopiperidin-4-yl)acetyl)amino)-2-(4-(methoxymethyl)phenyl)acetamide To a solution of (R)-2-amino-N-(4-(tert-butyl)-3-fluorophenyl)-2-(4-(methoxymethyl)phenyl)acetamide (50 mg, 0.15 mmol), DIEA (0.050 mL, 0.29 mmol) and 2-(2,6-dioxopiperidin-4-yl)acetic acid (27.3 mg, 0.16 mmol) in DMF (2.0 mL) was added HATU (66.2 mg, 0.17 mmol) at room temperature, and the mixture was stirred for 2 hr. To the reaction mixture were added water and ethyl acetate, and the organic layer was separated. The organic layer was washed with brine, and dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent; ethyl acetate/hexane), and crystallized from ethyl acetate/hexane to give the title compound (21.9 mg, 0.044 mmol, 30.3%) as white crystals. MS(API): Calculated 497.6, Found 498.2(M+H) 1H NMR (300 MHz,DMSO-d6) : delta1.29 (9H, s), 2.20-2.40 (5H, m), 3.27 (3H, s), 3.30 (2H,s), 4.38 (2H,s), 5.57 (1H, d, J=7.2 Hz), 7.16-7.35 (4H, m), 7.40-7.54 (3H, m), 8.75 (1H, d, J=7.2 Hz), 10.46 (1H, s), 10.71 (1H, s).
As the paragraph descriping shows that 6258-28-2 is playing an increasingly important role.
Reference：
Patent; Takeda Pharmaceutical Company Limited; YAMAMOTO, Satoshi; SHIRAI, Junya; KONO, Mitsunori; TOMATA, Yoshihide; SATO, Ayumu; OCHIDA, Atsuko; FUKASE, Yoshiyuki; FUKUMOTO, Shoji; ODA, Tsuneo; TOKUHARA, Hidekazu; ISHII, Naoki; SASAKI, Yusuke; (255 pag.)EP3018123; (2016); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem